AGP Picks
View all

Vabysmo market seen growing on retinal disease demand, aging population

10 hours ago
Vabysmo market seen growing on retinal disease demand, aging population
By AI, Created 14:00 UTC, Nov 19, 2026, AGP -

The Business Research Company says the Vabysmo market is set for expansion through 2035 as demand rises for retinal disease treatments and longer-lasting eye therapies. North America led the global market in 2025, while aging populations and higher rates of ophthalmic disease are expected to support future growth.

Why it matters: - Vabysmo targets age-related macular degeneration and diabetic macular edema, two major causes of vision loss. - The market’s outlook reflects broader demand for retinal therapies that can reduce injection frequency and preserve vision. - Growth in ophthalmic disease and aging populations could expand use of long-acting biologic treatments.

What happened: - The Business Research Company published Vabysmo Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Vabysmo market gained attention as retinal disease treatments continued to advance. - North America dominated the global Vabysmo market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also published a free sample report.

The details: - Vabysmo is a prescription eye medicine used to treat retinal conditions including AMD and DME. - The drug inhibits VEGF and Ang-2 proteins. - That action helps reduce fluid buildup in the retina and helps prevent further vision loss. - Vabysmo is given through eye injections. - The treatment is positioned as a longer-acting option that requires fewer injections than traditional therapies. - Historical market growth was driven by better detection of retinal disease, more specialized ophthalmology clinics, anti-VEGF treatment success, a growing elderly population and broader access to intravitreal injection procedures. - Future market growth is expected to come from more diabetic eye disease, demand for longer-lasting treatment effects, growth in personalized ophthalmic care, more investment in retinal drug development and progress in biologic drug delivery technologies. - The report highlights wider use of long-acting retinal therapies, more interest in reducing injection frequency, dual-target ophthalmic drugs, stronger focus on vision preservation and more advanced biologic formulations as key trends. - Rising ophthalmic disease is a major driver, including dry eyes, cataracts, glaucoma and macular degeneration. - The report links that rise to aging populations, higher diabetes rates, lifestyle factors, improved diagnostics and longer life expectancy. - The Welsh Government reported more than 35,000 ophthalmology admissions in Wales in 2023-24, up 5.8% from the prior year. - The Population Reference Bureau said in January 2024 that the number of Americans 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, a 47% increase.

Between the lines: - The report points to a market shaped less by one breakthrough drug and more by a sustained shift toward chronic eye-disease management. - The emphasis on fewer injections suggests payers, doctors and patients may favor therapies that reduce treatment burden. - North America’s lead likely reflects earlier adoption of specialty ophthalmology care and stronger access to advanced retinal treatments.

What's next: - The market outlook through 2035 will hinge on adoption of long-acting therapies and new biologic delivery methods. - Demand should track diagnosis rates for diabetic eye disease and other retinal conditions. - The company is promoting the full report and expert contact channels for additional market details.

The bottom line: - Vabysmo sits in a market expected to grow as retinal disease becomes more common and treatment preferences shift toward longer-lasting, lower-burden options.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

United Kingdom Political Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

United Kingdom Political Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.